<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Parkinsonism & Neurodegenerative Disorders | CNS Pharmacology</title>
    
    <!-- Preconnect for performance -->
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    
    <!-- Google Fonts -->
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    
    <!-- Main Stylesheet -->
    <link rel="stylesheet" href="../styles/main.css">
    
    <!-- MathJax Configuration -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <!-- Skip Link for Accessibility -->
    <a href="#main-content" class="skip-link">Skip to main content</a>
    
    <!-- Reading Progress Bar -->
    <div class="reading-progress-container" aria-hidden="true">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <!-- Theme Toggle -->
    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode" title="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <div class="page-wrapper">
        <!-- Floating Mini-TOC -->
        <aside class="floating-toc" id="floating-toc" aria-label="On this page">
            <div class="floating-toc-header">
                <span class="floating-toc-icon">üìë</span>
                <span>On this page</span>
            </div>
            <nav class="floating-toc-nav">
                <ul class="floating-toc-list">
                    <!-- Populated by JS -->
                </ul>
            </nav>
        </aside>

        <div class="container">
            <article class="document-article" role="main" id="main-content">
                <!-- Top Navigation -->
                <nav class="document-nav" role="navigation" aria-label="Document navigation">
                    <div class="nav-container">
                        <a href="../index.html" class="nav-button nav-button--toc" aria-label="Table of Contents">
                            <span class="nav-icon">üìö</span>
                            <span class="nav-text">Contents</span>
                        </a>
                        
                        <a href="01-antipsychotics-lithium.html" class="nav-button nav-button--prev" aria-label="Previous section">
                            <span class="nav-icon">‚Üê</span>
                            <span class="nav-text">Previous</span>
                        </a>
                        
                        <div class="document-progress">
                            <div class="progress-indicator">
                                <span class="progress-current">2</span>
                                <span class="progress-separator">/</span>
                                <span class="progress-total">2</span>
                            </div>
                            <div class="progress-bar-container" aria-hidden="true">
                                <div class="progress-bar-fill" style="width: 100%;"></div>
                            </div>
                            <span class="progress-label">Parkinsonism & Neurodegenerative Disorders</span>
                        </div>
                        
                        <!-- Next button disabled (Last topic) -->
                        <span class="nav-button nav-button--next disabled" aria-disabled="true">
                            <span class="nav-text">Next</span>
                            <span class="nav-icon">‚Üí</span>
                        </span>
                    </div>
                </nav>

                <!-- Breadcrumb -->
                <nav class="breadcrumb" aria-label="Breadcrumb">
                    <ol class="breadcrumb-list">
                        <li class="breadcrumb-item"><a href="../index.html">Home</a></li>
                        <li class="breadcrumb-item"><a href="#">CNS Pharmacology</a></li>
                        <li class="breadcrumb-item active" aria-current="page">Parkinsonism & Neurodegenerative Disorders</li>
                    </ol>
                </nav>

                <!-- Document Header -->
                <header class="document-header">
                    <div class="header-badge">
                        <span class="badge-icon">üß†</span>
                        <span class="badge-text">Neuropharmacology</span>
                    </div>
                    <h1 class="document-title">Drugs Used in Parkinsonism & Other Movement Disorders</h1>
                    <div class="title-meta">
                        <span class="meta-item">
                            <span class="meta-icon">üë§</span>
                            <span>Mutiso Urbanus</span>
                        </span>
                        <span class="meta-item">
                            <span class="meta-icon">‚è±Ô∏è</span>
                            <span>30 min read</span>
                        </span>
                    </div>
                </header>

                <!-- Main Content Area -->
                <div class="content-wrapper">
                    
                    <!-- START: introduction -->
                    <section id="introduction" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">01</div>
                            <h2 class="section-title">Introduction to Neurodegenerative Diseases</h2>
                        </div>

                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Neurologic conditions include parkinsonism, Huntington's disease, Wilson's disease, and Gilles de la Tourette's syndrome</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Parkinson's and Alzheimer's diseases are the two neurodegenerative disorders that respond to drug therapy</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Movement disorders that constitute these neurologic conditions include; <strong>atherosis</strong>, <strong>chorea</strong>, <strong>dyskinesia</strong>, <strong>dystonia</strong>, <strong>tics</strong>, and <strong>tremor</strong>.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">They can be caused by a variety of general medical conditions, neurologic dysfunction, and drugs</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Parkinsonism is a movement disorder that involves dysfunction in the basal ganglia and associated brain structures</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Signs include rigidity of skeletal muscles, akinesia (or bradykinesia), flat facies, and tremor at rest</span>
                                </li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: introduction -->

                    <!-- START: parkinsonism-types -->
                    <section id="parkinsonism-types" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">02</div>
                            <h2 class="section-title">Types of Parkinsonism</h2>
                        </div>

                        <div class="content-card">
                            <h3>Naturally Occurring Parkinsonism</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">It is characterised by a decrease in the levels of dopamine (in the striatal) and degeneration of dopaminergic neurons (in the nigrostriatal tract)</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">The GABAergic neurons are of the \(\mathrm{D}_{2}\) subclass (negatively coupled to adenylyl cyclase)</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">The reduction of normal dopaminergic neurotransmission leads to excessive excitatory actions of cholinergic neurons</span>
                                </li>
                            </ul>
                        </div>

                        <div class="content-card">
                            <h3>Drug induced</h3>
                            <p>Result from:</p>
                            <ol class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">By blockage of brain dopamine receptors; e.g. Butyrophenone and phenothiazine antipsychotic drugs</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Depletion of brain dopamine; reserpine at high doses,</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Destruction of dopaminergic neurons in the nigrostriatal tract; may causes irreversible parkinsonism
                                        <br>MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a by-product of the attempted synthesis of an illicit meperidine analogue,
                                    </span>
                                </li>
                            </ol>
                        </div>

                        <div class="content-card">
                            <h3>Strategy of drug therapy</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Dopamine and acetylcholine activities are out of balance in parkinsonism</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Many of the symptoms of parkinsonism reflect an imbalance between the excitatory cholinergic neurons and the greatly diminished number of inhibitory dopaminergic neurons</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Therapy is aimed at restoring dopamine in the basal ganglia and antagonizing the excitatory effect of cholinergic neurons, thus re-establishing the correct dopamine/acetylcholine balance</span>
                                </li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: parkinsonism-types -->

                    <!-- START: drugs-parkinson -->
                    <section id="drugs-parkinson" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">03</div>
                            <h2 class="section-title">Drugs used in Parkinson's Disease</h2>
                        </div>

                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Levodopa (dopamine preccursor)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Carbidopa</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Bromocriptine (dopamine agonist)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Pramipexole (dopamine agonist)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Selegiline (MAOI)entacapone (COMT inhibitor)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Benztropine (muscarinic antagonist)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Amantadine</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Procyclidine</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Entacapone</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Biperidine</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Apomorphine, etc</span></li>
                            </ul>
                        </div>

                        <!-- Levodopa & Carbidopa -->
                        <div class="content-card">
                            <h3>1. Levodopa & Carbidopa</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Levodopa is a precursor of dopamine</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Dopamine has low bioavailability and does not readily cross the blood-brain barrier; its precursor, L-dopa (levodopa), is therefore used</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Usually given in combination with Carbidopa</span></li>
                            </ul>

                            <h4>Mechanism of Action (MOA)</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Because parkinsonism results from insufficient dopamine in specific regions of the brain, L-dopa attempts to replenish the dopamine deficiency.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Dopamine itself does not cross the blood-brain barrier, but its immediate precursor, levodopa, is actively transported into the CNS</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">L-dopa restores dopaminergic neurotransmission in the corpus striatum by enhancing the synthesis of dopamine in the surviving neurons of the substantia nigra</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">L-Dopa enters the brain and is converted to dopamine by the enzyme dopa decarboxylase</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">The enzyme "dopa decarboxylase" is present in many body tissues, including the brain; therefore given in combination with carbidopa</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Carbidopa:</strong> a dopa decarboxylase inhibitor that does not cross the blood-brain barrier; it inhibits dopa decarboxylase in peripheral thus diminishes the metabolism of levodopa in the gastrointestinal tract and peripheral tissues</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">This increases the availability of levodopa to the CNS</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">This combination prolongs the plasma halflife, enhance effectiveness of lower doses of levodopa and therefore result in fewer peripheral side effects</span></li>
                            </ul>

                            <h4>Actions</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">The drug does not cure parkinsonism</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Levodopa decreases the rigidity, tremors, and other symptoms of parkinsonism</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Decreases the mortality rate</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Nb//Responsiveness fluctuates and gradually decreases with time, which may reflect progression of the disease</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Clinical response fluctuations may, in some cases, be related to the timing of levodopa dosing</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">In early disease the therapeutic response to levodopa is consistent, and the patient rarely complains that the drug effects a <strong>wear</strong> of
                                    <br>Reason being the number of residual dopaminergic neurons in the substantia nigra (typically about 20 percent of normal) is adequate for conversion of levodopa to dopamine
                                </span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">In other cases the on-off phenomena is experienced; (motor control fluctuation develops)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">with time the number of neurons decreases, and fewer cells are capable of taking up exogenously administered levodopa and converting it to dopamine for subsequent storage and release</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Relief provided by levodopa is only symptomatic, and it lasts only while the drug is present in the body.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Off-periods may respond to apomorphine.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Drug holidays sometimes reduce toxic effects but rarely affect response fluctuations</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Catechol-o-methyltransferase (COMT) inhibitors used adjunctively may improve fluctuations in levodopa responses in some patients</span></li>
                            </ul>

                            <h4>Pharmacokinetics (PK)</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">The drug is absorbed rapidly from the small intestine when taken on an empty stomach</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Levodopa has an extremely short half-life (1 to 2 hours</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Ingestion of meals, particularly if high in protein, interferes with the transport of levodopa into the CNS</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Large, neutral amino acids (for example, leucine and isoleucine) compete with levodopa for absorption from the gut and for transport across the blood-brain barrier</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Thus, levodopa should be taken on an empty stomach, typically 45 minutes before a meal</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Withdrawal from the drug must be gradual</span></li>
                            </ul>

                            <h4>Toxicity</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Most adverse effects are dose dependent</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Gastrointestinal effects: include anorexia, nausea, and emesis and can be reduced by taking the drug in divided doses</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Tolerance to the emetic action of levodopa usually occurs after several months</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Postural hypotension especially in the early stage of treatment. Other cardiac effects include tachycardia, asystole, and cardiac arrhythmias (rare)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Dyskinesias occur in up to \(80 \%\) of patients, with choreoathetosis of the face and distal extremities occurring most often. Some patients may exhibit chorea, ballismus, myoclonus, tics, and tremor.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Behavioral effects may include anxiety, agitation, confusion, delusions, hallucinations, and depression.</span></li>
                            </ul>

                            <aside class="callout callout--warning">
                                <div class="callout-header">
                                    <span class="callout-icon">‚ö†Ô∏è</span>
                                    <span class="callout-title">Interactions</span>
                                </div>
                                <div class="callout-content">
                                    <ul class="enhanced-list">
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">The vitamin pyridoxine \(\left(\mathrm{B}_{6}\right)\) increases the peripheral breakdown of levodopa and diminishes its effectiveness</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Concomitant administration of levodopa and monoamine oxidase (MAO) inhibitors, such as phenelzine, can produce a hypertensive crisis caused by enhanced catecholamine production</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">In many psychotic patients, levodopa exacerbates symptoms, possibly through the buildup of central catecholamines.</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">In patients with glaucoma, the drug can increase intraocular pressure</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Cardiac patients should be carefully monitored coz of the possible development of cardiac arrhythmias</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Antipsychotic drugs are generally contraindicated in parkinsonian patients; potently block dopamine receptors and produce a parkinsonian syndrome themselves</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Low doses of atypical antipsychotic agents can be employed to manage levodopa-induced psychiatric symptoms</span></li>
                                    </ul>
                                </div>
                            </aside>
                        </div>

                        <!-- Dopamine Agonists -->
                        <div class="content-card">
                            <h3>2. Dopamine Agonists</h3>
                            <p>Include:</p>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Bromocriptine</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Non-ergot drugs</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Apomorphine</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">ropinirole,</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">pramipexole and</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">rotigotine</span></li>
                            </ol>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Bromocriptine, pramipexole, and ropinirole are all effective in patients with advanced Parkinson's disease complicated by motor fluctuations and dyskinesias</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">They are however ineffective in patients who have shown no therapeutic response to levodopa</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Apomorphine is also used in severe and advanced stages of the disease as an injectable dopamine agonist to supplement the oral medications</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Side effects severely limit the utility of the dopamine agonists</span></li>
                            </ul>

                            <h4>Bromocriptine</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">An ergot alkaloid</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>MOA:</strong> Acts as a partial agonist at dopamine \(D_{2}\) receptors in the brain</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">It increases the functional activity of dopamine neurotransmitter pathways, including those involved in extrapyramidal functions</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Can be used as monotherapy or in combination with L-dopa or other anticholinergic drugs</span></li>
                            </ul>

                            <h4>Common ADRs include:</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Anorexia</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">nausea and vomiting and</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">postural hypotension</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Orthostatic hypotension</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Dyskinesia (but less prominent than in levodopa</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Behavioral effects: more with bromocriptine than with newer dopamine agonists; include confusion, hallucinations, and delusions</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">The actions of bromocriptine are similar to those of levodopa, except that hallucinations, confusion, delirium, nausea, and orthostatic hypotension are more common</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Dyskinesia is less prominent</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">In psychiatric illness, bromocriptine and levodopa may cause the mental condition to worsen</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Serious cardiac problems may develop, particularly in patients with a history of myocardial infarction</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Worsen vasospasm occurs, in patients with peripheral vascular disease</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">worsen peptic ulcer</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Being a is an ergot derivative, bromocriptine has the potential to cause pulmonary and retroperitoneal fibrosis</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">NB//Dose of bromocriptine is increased gradually during a period of 2 to 3 months</span></li>
                            </ul>

                            <h4>Non-ergot drugs (Apomorphine, Rotigotine, Pramipexole)</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Apomorphine is available in injectable and Rotigotine is available in transdermal delivery</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Are dopamine agonists</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Apomorphine is meant to be used for the acute management of the hypomobility phenomenon</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">They alleviate the motor deficits in both patients who have never been treated with levodopa and patients with advanced Parkinson's disease who are taking levodopa</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Dopamine agonists may delay the need to employ levodopa therapy in early Parkinson's disease and may decrease the dose of levodopa in advanced Parkinson's disease</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Adverse effects:</strong> Nausea, hallucinations, insomnia, dizziness, constipation, and orthostatic hypotension are among the more distressing side effects of these drugs; dyskinesias are less frequent than with levodopa.</span></li>
                            </ul>

                            <aside class="callout callout--warning">
                                <div class="callout-header">
                                    <span class="callout-icon">‚ö†Ô∏è</span>
                                    <span class="callout-title">Drug Interaction</span>
                                </div>
                                <div class="callout-content">
                                    <ul class="enhanced-list">
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Pramipexole dependence on renal function for its elimination</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Cimetidine inhibits renal tubular secretion of organic bases; increases the half-life of pramipexole by 40 percent</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Fluoroquinolone antibiotics and other inhibitors of the CYP450-1A2 hepatic enzyme have been shown to inhibit the metabolism of ropinirole</span></li>
                                    </ul>
                                </div>
                            </aside>
                        </div>

                        <!-- Other Parkinson's Drugs -->
                        <div class="content-card">
                            <h3>3. Monoamine Oxidase Inhibitors</h3>
                            <p><strong>Selegiline and rasagilene</strong></p>
                            <p><strong>MOA:</strong> Are selective inhibitors of monoamine oxidase type B, the enzyme that metabolizes dopamine</p>
                            <h4>Clinical Use</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Selegiline has minimal efficacy in parkinsonism if given alone, but can be used adjunctively with levodopa</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Rasagiline irreversibly and selectivly inhibit brain MAO Type B, has five times the potency of selegiline and has been used as monotherapy in early symptomatic parkinsonism as well as in combinations with levodopa</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Selegiline is metabolized to methamphetamine and amphetamine, whose stimulating properties may produce insomnia if the drug is administered later than midafternoon</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Selegiline metabolite, desmethylselegiline is neuroprotective</span></li>
                            </ul>

                            <h3>4. Catechol-O-methyltransferase (COMT) inhibitors</h3>
                            <p><strong>Entacapone or tolcapone</strong></p>
                            <h4>Mechanism of Action</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">They selectively and reversibly inhibit COMT</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Levodopa is methylated by catechol-Omethyltransferase (COMT); Normally a minor pathway for levodopa metabolism to 3-Omethyldopa</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Inhibition of peripheral dopamine decarboxylase activity by carbidopa, increase the concentration of 3-O-methyldopa that competes with levodopa for active transport into the CNS</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Entacapone or tolcapone inhibit COMT leading to decreased plasma concentrations of 3-O-methyldopa, increased central uptake of levodopa, and greater concentrations of brain dopamine</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">They reduce the symptoms of wearing-off phenomena seen in patients on levodopacarbidopa</span></li>
                            </ul>

                            <h4>Pharmacokinetics & Adverse Effects</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Oral absorption of both drugs occurs readily and is not influenced by food</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">They are extensively bound to plasma albumin ( \(>98 \%\) )</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Have a limited volumes of distribution</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Tolcapone penetrates the blood-brain barrier and inhibits COMT in the CNS: entacapone does not</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">The Inhibition of COMT in the periphery is however the primary therapeutic action</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Adverse effects:</strong> Diarrhea, postural hypotension, nausea, anorexia, dyskinesias, hallucinations, and sleep disorders.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Hepatic necrosis with tolcapone use; appropriate hepatic function monitoring is needed: use only in patients whom other modalities have failed</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Entacapone does not exhibit this toxicity and has largely replaced tolcapone</span></li>
                            </ul>

                            <h3>5. Amantadine</h3>
                            <p>An the antiviral drug used in RX of influenza has an antiparkinsonism action</p>
                            <h4>MOA & Effects:</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">It increase the release of dopamine, block cholinergic receptors, and inhibiting the N-methyl-D-aspartate (NMDA) type of glutamate receptors</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Its action at NMDA receptors as the primary action at therapeutic concentrations</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Note: Amantadine has no effect if dopamine release is already at a maximum</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">May cause restlessness, agitation, confusion, and hallucinations</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">At high doses, it may induce acute toxic psychosis</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Orthostatic hypotension</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Urinary retention</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Peripheral edema</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Dry mouth also may occur</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Nb//Tolerance develops readily</span></li>
                            </ul>

                            <h3>6. Antimuscarinic agents</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">The antimuscarinic agents are much less efficacious than levodopa</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">They include: benztropine, trihexyphenidyl, procyclidine and biperiden</span></li>
                            </ul>
                            <h4>MOA & Adverse Effects:</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Blockage of cholinergic transmission produces effects similar to augmentation of dopaminergic transmission ( because of the creation of an imbalance in the dopamine/acetylcholine ratio)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">All of these drugs can induce mood changes and produce xerostomia (dryness of the mouth) and visual problems, as do all muscarinic blockers</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">They interfere with gastrointestinal peristalsis</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Are contraindicated in patients with glaucoma, prostatic hyperplasia, or pyloric stenosis</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Adverse effects: dilation of the pupil, confusion, hallucination, sinus tachycardia, urinary retention, constipation, dry mouth</span></li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: drugs-parkinson -->

                    <!-- START: pharmacologic-intervention -->
                    <section id="pharmacologic-intervention" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">04</div>
                            <h2 class="section-title">Pharmacologic Intervention in Other Neurodegenerative Disorders</h2>
                        </div>

                        <div class="content-card">
                            <h3>Alzheimer's disease</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Pharmacologic intervention is only palliative and provides modest short-term benefit.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">None of the currently available therapeutic agents have been shown to alter the underlying neurodegenerative process.</span></li>
                            </ul>
                            <p>Dementia of the Alzheimer's type has three distinguishing features:</p>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">accumulation of senile plaques ( \(\beta\)-amyloid accumulations),</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">formation of numerous neurofibrillary tangles,</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">loss of cortical neurons; particularly cholinergic neurons</span></li>
                            </ol>
                        </div>

                        <div class="content-card">
                            <h3>Drug Therapy</h3>
                            <p>Current therapies are aimed at either improving cholinergic transmission within the CNS or preventing excitotoxic actions resulting from overstimulation of N-methyl-D-aspartic acid (NMDA)-glutamate receptors in selected brain areas</p>
                            <h4>Include:</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Acetylcholinesterase inhibitors</span></li>
                            </ul>

                            <h4>Acetylcholinesterase inhibitors</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">AChE inhibitors are approved for the treatment of mild to moderate Alzheimer's disease Include:
                                    <br>Donepezil, galantamine, rivastigmine, tacrine
                                </span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Memory loss that is a hallmark symptom of Alzheimer's disease is linked to the Progressive loss of cholinergic neurons and, presumably, cholinergic transmission within the cortex to the</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Inhibition of acetylcholinesterase (AChE) within the CNS improve cholinergic transmission at the neurons that are still functioning</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">These drugs provide a modest reduction in the rate of loss of cognitive functioning in Alzheimer's patients</span></li>
                            </ul>

                            <h4>NMDA-receptor antagonist</h4>
                            <p><strong>E.g. Memantine</strong></p>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Stimulation of glutamate receptors in the CNS appears to be critical for the formation of certain memories; however, overstimulation of glutamate receptors, particularly of the NMDA type, has been shown to result in excitotoxic effects on neurons and is suggested as a mechanism for neurodegenerative or apoptotic (programmed cell death) processes</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Binding of glutamate to the NMDA receptor assists in the opening of an associated ion channel that allows \(\mathrm{Na}^{+}\) and, particularly, \(\mathrm{Ca}^{2+}\) to enter the neuron</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Unfortunately, excess intracellular \(\mathrm{Ca}^{2+}\) can activate a number of processes that ultimately damage neurons and lead to apoptosis</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Antagonists of the NMDA-glutamate receptor are often neuroprotective, preventing the loss of neurons following ischemic and other injuries.</span></li>
                            </ul>

                            <h4>Memantine MOA</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Memantine acts by physically blocking the NMDA receptor associated ion channel, but at therapeutic doses, only a fraction of these channels are actually blocked</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">This limit \(\mathrm{Ca}^{2+}\) influx into the neuron such that toxic intracellular levels are not achieved during NMDA receptor overstimulation, while still permitting sufficient \(\mathrm{Ca}^{2+}\) flow through unblocked channels to preserve other vital processes that depend on \(\mathrm{Ca}^{2+}\) (or \(\mathrm{Na}^{+}\)) influx through these channels</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Memantine is well tolerated,</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Has few dose-dependent adverse events such as:
                                    <ul class="enhanced-list">
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">confusion,</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">agitation, and</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Restlessness; which are indistinguishable from the symptoms of Alzheimer's disease</span></li>
                                    </ul>
                                </span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Owing to its different mechanism of action and possible neuroprotective effects, memantine is often given in combination with an AChE inhibitor</span></li>
                            </ul>
                        </div>

                        <div class="content-card">
                            <h3>Drugs for other movement disorders</h3>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Tremor; propranolol</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Huntington's & tourette's- haloperidol & tetrabenazine</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Wilson disease; penicillamine</span></li>
                            </ol>
                            <h4>Other drugs</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Donepezil</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Galantamine</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Memantine</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Rivostigmine</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Tacrine</span></li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: pharmacologic-intervention -->

                    <!-- Key Points Section -->
                    <aside class="key-points-section" role="region" aria-labelledby="key-points-title">
                        <div class="key-points-wrapper">
                            <div class="key-points-header">
                                <span class="key-points-icon">‚≠ê</span>
                                <h3 id="key-points-title" class="key-points-title">Key Points</h3>
                            </div>
                            <ul class="key-points-list">
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Levodopa is a precursor of dopamine</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Dopamine itself does not cross the blood-brain barrier, but its immediate precursor, levodopa, is actively transported into the CNS</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Carbidopa: a dopa decarboxylase inhibitor that does not cross the blood-brain barrier</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Relief provided by levodopa is only symptomatic, and it lasts only while the drug is present in the body.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Pharmacologic intervention is only palliative and provides modest short-term benefit.</strong></p>
                                </li>
                            </ul>
                        </div>
                    </aside>
                </div>

                <!-- Bottom Navigation -->
                <nav class="document-nav document-nav--bottom" role="navigation" aria-label="Document navigation">
                    <div class="nav-container">
                        <a href="01-antipsychotics-lithium.html" class="nav-button nav-button--prev nav-button--large">
                            <span class="nav-icon">‚Üê</span>
                            <div class="nav-content">
                                <span class="nav-label">Previous</span>
                                <span class="nav-title">Antipsychotics</span>
                            </div>
                        </a>
                        
                        <a href="../index.html" class="nav-button nav-button--toc">
                            <span class="nav-icon">üìö</span>
                            <span class="nav-text">All Topics</span>
                        </a>
                        
                        <!-- Next button placeholder -->
                        <span class="nav-button nav-button--next nav-button--large disabled" aria-disabled="true">
                            <div class="nav-content">
                                <span class="nav-label">Next</span>
                                <span class="nav-title">End of Guide</span>
                            </div>
                            <span class="nav-icon">‚Üí</span>
                        </span>
                    </div>
                </nav>
            </article>
        </div>
    </div>

    <!-- Scripts -->
    <script src="../js/theme.js"></script>
    <script src="../js/navigation.js"></script>
    <script src="../js/interactions.js"></script>
</body>
</html>